Regarding diabetes retrieval, I asked the specific question: "Does the CIAB technology meet the retrieval requirements of the FDA for diabetes?" The answer I received: "If the capsules need to be retrieved they can be, depending in where they are placed in the body. If they are placed in a location where there might be a possibility of their migration, they can be contained in some way so as to make their retrieval (along with the cells inside them) possible. Please always keep in mind that the genetically transformed cells cannot escape from the CIAB capsules."
So, they are talking in terms of "if", "depending", etc. To me, that isn't really a plan. Like you said, after years of working on diabetes, and especially with the consortium experts, you would certainly think they would have something more concrete with regarding to solving the retrievability problem. Why they don't...well your guess is as good as mine. But if we are guessing about possibilities, I wouldn't sleep on Novo Nordisk. Very late 2016 their senior management admitted that finding a viable encapsulation platform was the only roadblock for their stem cell diabetes treatment. He also admitted they "are collaborating with certain groups on technology to encapsulate the transplanted cells to help protect them". But he wouldn't name any names.
News 
Market Data 
Discover 
AI
